Ropinirole tablets recalled due to FDA manufacturing compliance deviations
Accord Healthcare recalls 139,332 bottles of ropinirole 0.25 mg tablets distributed in the US, Puerto Rico, and Canada due to manufacturing compliance deviations identified during FDA inspection.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II classification indicates potential for adverse health consequences. No illnesses or injuries are reported in the source. The specific CGMP deviations are not detailed, making this a risk-of-harm situation where injury has not yet been reported, meeting the rubric criterion for High severity.
Plain-English summary
Accord Healthcare, Inc. is recalling ropinirole 0.25 mg tablets due to Current Good Manufacturing Practice (CGMP) deviations identified during an FDA inspection. The recall affects 139,332 bottles distributed in the United States, Puerto Rico, and Canada.
The recalled ropinirole tablets were manufactured by Intas Pharmaceuticals Limited in India and distributed under Accord Healthcare, Inc. Multiple batches are affected, with expiration dates ranging from March 2023 to May 2024. The involved lot numbers are P2102086, P2105093-P2105097, P2106490-P2106494, P2201067-P2201069, and P2203516.
Individuals taking the recalled medication should contact their healthcare provider or pharmacist for guidance on whether to continue or discontinue use.
The recalled product
- Product
- ROPINIROLE (ROPINIROLE)
- Brand
- ROPINIROLE
- Manufacturer
- Accord Healthcare, Inc.
- Category
- Drug
- Hazard
- cgmp-deviation
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (20)
- Batches: P2102086
- Exp. Date 3/31/2023
- P2105094
- P2105095
- P2105097
- P2105096
- P2105093
- Exp. Date 7/31/2023
- P2106490
- P2106491
- P2106493
- P2106492
- P2106494
- Exp. Date 9/30/2023
- P2201069
- P2201068
- P2201067
- Exp. Date 1/31/2024
- P2203516
- Exp. Date 5/31/2024
UPCs (1)
- 316729232012
Distribution
Distribution scope not specified by the agency.
Related recalls
Same brand · ROPINIROLE
- HighFDA Recalls Ropinirole 3mg Tablets due to CGMP Deviations
FDA (Drugs) · 2023-03-08
- ModerateRopinirole Tablets Recalled Due to Manufacturing Quality Violations
FDA (Drugs) · 2023-03-08
- ModerateRopinirole Tablets Recalled by Accord Healthcare Following FDA Inspection
FDA (Drugs) · 2023-03-08
- HighRopinirole tablets recalled due to manufacturing practice deviations
FDA (Drugs) · 2023-03-08
- ModerateRopinirole Tablets Recalled Due to Manufacturing Practice Deviations
FDA (Drugs) · 2023-03-08
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27